(Jerusalem/Geneva Composite Electric) an preliminary data of Israeli experiments show that the fourth dose of Pfizer Crown disease vaccine can help improve the level of antibody, but it is still not enoughEffectively prevent mutant strain Omikon.At the same time, American pharmacist Modner plans to launch a vaccine addition agent that can defensive crown disease, influenza, and respiratory tract sympathetic virus at the end of next year.
Legff, Director of Infectious Diseases of the Israeli Sheba Medical Center, announced on the 17th of this month that the center was inoculated by the two groups of staff to take over the second dose; followed, one week later, a week laterAnalyze the data of 120 inoculating Modner Additional agents, and analyze the data of 154 inoculaers two weeks later.The Modner group had previously inoculated three doses of Pfizer vaccine.After comparing these two sets of data with the control group of the fourth injection person, the research team found that the level of the two groups of personnel with the rising of the two groups of personnel in the fourth shot was similar.
The most infectious non -symptom of the first three days of infection is reduced to five days
ReagffChief researcher.She said that the fourth dose of Pfizer's vaccine was "very effective" for the previous mutant strains and was relatively weak for Omikon's defense.Nevertheless, the infected people in the test only have mild or asymptomatic.
Her online press conference said: "We now know that the level of antibody in the infection of Omikon may be very high, and even a good vaccine cannot meet the standards."
Israel is one of the countries that take the lead in vaccination a year ago.Due to the surge in domestic cases in the near future, Israel has taken the lead in the fourth dose of the fourth dose for the at least 60 years old and weak immunity at the end of December.
Reegff -Jochi said that the decision to inoculate the fourth dose for the susceptible population is correct, because it may provide additional protection for Omiko, but the test results are not enough to be enoughSupport to allow the overall population to be widely vaccinated for the fourth dose.
According to the Ministry of Health of Israel, more than 537,000 people have vaccinated the fourth dose of vaccine so far; more than 80 % of adults vaccinated two doses, and more than half of them were vaccinated.
The Israeli Ministry of Health also announced on Monday that due to the most contagious first three days of the diagnostic, the authorities have shortened the severity of the asymptomatic diagnostic from seven days to five days.
Israeli Prime Minister Berneter said in a short video that Omircorr caused surge in cases and isolation, which constitutes a burden on the economy."This decision will enable us to maintain public hygiene on the one hand, and keep the economy in operation, and ensure that we can spend this wave in peace."Three -in -one vaccine such as diseases and influenza
On the other hand, Modner, an American pharmaceutical dealer, plans to launch an at the end of 2023 to prevent crown diseases, influenza, and respiratory tract syndicate (RespiratorsyNcytialvirus) Vaccine addition agent, hopes that this three -in -one vaccine that only inoculates one dose per year can encourage people to vaccinate each year.
The respiratory cytotrobiosis is a common virus that causes a cold. Baby and elderly people will cause severe symptoms after infection.
Modner President Bangsers participated in the World Economic Forum meeting through a video on the 17th of this month: "Our goal is to have an vaccine additional agent that is vaccinated once a year, so that we will not be on.When encountering the public, they do not comply with the prescribed problems, for example, some people do not want to take two or three stitches in a winter, but they are only willing to inject it once. "Entering the third phase of clinical trials, the human body test at the final stage; the influenza part is estimated to enter the final stage in the second quarter of this year.
